Ceplene/Interleukin-2 combination approved for treatment of malignant melanoma


Source: www.pharmalive.com Maxim Pharmaceuticals announced that its treatment protocol to provide its investigational drug Ceplene, in combination with interleukin-2 (IL-2), for treatment of patients with advanced malignant melanoma, has been approved by the FDA. The protocol allows Maxim to provide expanded access of Ceplene to patients in the United States while a Phase III clinical trial continues.

Related Videos
© 2023 MJH Life Sciences

All rights reserved.